Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin

Clinical Pharmacokinetics

Volumn 52, Issue 12, 2013, Pages 1111-1125

  Pérez Ruixo, Carlos ^a   Valenzuela, Belén ^b   Peris, José Esteban ^a   Bretcha Boix, Pedro ^b   Escudero Ortiz, Vanesa ^b   Farré Alegre, José ^b   Pérez Ruixo, Juan José ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c AMGEN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ICODEXTRIN; OXALIPLATIN;

ADULT; AGE; ARTICLE; BODY SURFACE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARCINOMATOUS PERITONITIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG BLOOD LEVEL; FEMALE; HALF LIFE TIME; HUMAN; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIA; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; SEX; SIMULATION; STATISTICAL MODEL; STEM CELL; SURGICAL STRESS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; HYPERTHERMIA, INDUCED; LEUKOCYTE COUNT; MODELS, BIOLOGICAL; NEUTROPENIA; NEUTROPHILS; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS;

EID: 84890528550     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0092-3     Document Type: Article

References (59)

1. Spiliotis JD. Peritoneal carcinomatosis cytoreductive surgery and HIPEC: a ray of hope for cure. Hepatogastroenterology. 2010;57:1173-7.
2. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-5.
3. Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113:315-25.
4. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-43.
5. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:1575-81.
6. Cao C, Yan TD, Black D, et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152-65.
7. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14:254-61.
8. Elias D, Pocard M, Goere D. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res. 2007;134:303-18.
9. Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18:18-25.
10. Elias D, El Otmany A, Bonnay M, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267-72.
11. Atallah D, Marsaud V, Radanyi C, et al. Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia. 2004;20:405-19.
12. Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137-45.
13. Ferron G, Dattez S, Gladieff L, et al. Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol. 2008;62:679-83.
14. Pérez-Ruixo C, Valenzuela B, Peris JE, et al. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery. Cancer Chemother Pharmacol. 2013;71:693-704.
15. Elias D, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis. Surg Oncol Clin North Am. 2003;12:755-69.
16. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol. 2000;45:157-64.
17. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713-21.
18. Valenzuela B, Nalda-Molina R, Bretcha-Boix P, et al. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis. AAPS J. 2011;13:72-82.
19. Tabuchi Y, Shinka S, Ishida H. The effects of anesthesia and surgery on count and function of neutrophils. J Anesth. 1989;3:123-31.
20. Beal SL, Sheiner LB, Boeckman AJ, editors. NONMEM users guides. Ellicott City: ICON Development Solutions; 1989-2006.
21. González-Sales M, Valenzuela B, Pérez-Ruixo C, et al. Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis®). Clin Pharmacokinet. 2012;51:751-64.
22. Quartino AL, Friberg LE, Karlsson MO. A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model. Invest New Drugs. 2012;30:833-45.
23. Vieira SM, Lemos HP, Grespan R, et al. A crucial role for TNF-alpha in mediating neutrophil influx induced by endogenously generated or exogenous chemokines, KC/CXCL1 and LIX/CXCL5. Br J Pharmacol. 2009;158:779-89.
24. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335-40.
25. Dale DC, Liles WC, Llewellyn C, Price TH. Effects of granulocyte- macrophage colony-stimulating factor (GM-CSF) on neutrophil kinetics and function in normal human volunteers. Am J Hematol. 1998;57:7-15.
26. Jagels MA, Hugli TE. Mechanisms and mediators of neutrophilic leukocytosis. Immunopharmacology. 1994;28:1-18.
27. Zhang L, Beal SL, Sheiner LB. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30:387-404.
28. Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558-69.
29. Kloft C, Wallin J, Henningsson A, et al. Population pharmacokinetic- pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12:5481-90.
30. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I: models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511-28.
31. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman and Hall/CRC Press; 1993.
32. Brendel K, Comets E, Laffont C, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036-49.
33. Nguyen TH, Comets E, Mentré F. Extension of NPDE for evaluation of nonlinear mixed effect models in presence of data below the quantification limit with applications to HIV dynamic model. J Pharmacokinet Pharmacodyn. 2012;39:499-518.
34. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143-51.
35. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17-20.
36. Dale DC, Fauci AS, Guerry D IV, et al. Comparison of agents producing a neutrophilic leukocytosis in man: hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest. 1975;56:808-13.
37. Joyce RA, Boggs DR. Visualizing the marrow granulocyte reserve. J Lab Clin Med. 1979;93:101-10.
38. Orr Y, Wilson DP, Taylor JM, et al. A kinetic model of bone marrow neutrophil production that characterizes late phenotypic maturation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R1707-16.
39. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187-97.
40. Kim C, Sakamoto A. Differences in the leukocyte response to incision during upper abdominal surgery with epidural versus general anesthesia. J Nippon Med Sch. 2006;73:4-9.
41. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31:318-24.
42. Krzyzanski W, Wiczling P, Lowe P, et al. Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J Clin Pharmacol. 2010;50:101S-12S.
43. Athens JW, Haab OP, Raab SO, et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest. 1961;40:989-95.
44. Gwak MS, Choi SJ, Kim JA, et al. Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med Sci. 2007;22:S104-8.
45. Dancey JT, Deubelbeiss KA, Harker LA, et al. Neutrophil kinetics in man. J Clin Invest. 1976;58:705-15.
46. Sandström M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin- cyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol. 2006;58:143-56.
47. Panetta JC, Schaiquevich P, Santana VM, et al. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res. 2008;14:318-25.
48. Ramon-Lopez A, Nalda-Molina R, Valenzuela B, et al. Semi-mechanistic model for neutropenia after high dose of chemotherapy in breast cancer patients. Pharm Res. 2009;26:1952-62.
49. Fliedner TM, Cronkite EP, Killmann SÅ, et al. Granulocytopoiesis: II. Emergence and pattern of labeling of neutrophils granulocytes in humans. Blood. 1964;24:683-700.
50. Duignan JP, Collins PB, Johnson AH, Bouchier-Hayes D. The association of impaired neutrophil chemotaxis with postoperative surgical sepsis. Br J Surg. 1986;73:238-40.
51. Solomkin JS, Bauman MP, Nelson RD, et al. Neutrophils dysfunction during the course of intra-abdominal infection. Ann Surg. 1981;194:9-17.
52. van Dijk WC, Verbrugh HA, van Rijswijk RE, et al. Neutrophil function, serum opsonic activity, and delayed hypersensitivity in surgical patients. Surgery. 1982;92:21-9.
53. Mollitt DL, Steele RW, Marmer DJ, et al. Surgically induced immunologic alterations in the child. J Pediatr Surg. 1984;19:818-22.
54. Walker RI, Willemze R. Neutrophil kinetics and the regulation of granulopoiesis. Rev Infect Dis. 1980;2:282-92.
55. Cartwright GE, Athens JW, Wintrobe MM. The kinetics of granulopoiesis in normal man. Blood. 1964;24:780-803.
56. Hing J, Perez-Ruixo JJ, Stuyckens K, Soto-Matos A, Lopez-Lazaro L, Zannikos P. Mechanism-based pharmacokinetic-pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia. Clin Pharmacol Ther. 2008;83:130-43.
57. Schmitt A, Gladieff L, Laffont CM, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28:4568-74.
58. Mohamed F, Sugarbaker PH. Carrier solutions for intraperitoneal chemotherapy. Surg Oncol Clin N Am. 2003;12:813-24.
59. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors. Eur J Cancer. 2006;42:2433-53.